◀ Back to PRKACG
GSK3B — PRKACG
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Luo et al., J Alzheimers Dis 2004
:
Independent of these effects, inhibition of
PKA by H89 ( 10 uM ) significantly
blocked TRH inhibition of
GSK-3 beta
Jensen et al., Cell Signal 2007
:
The
PKA inhibitor H89 ( 50 microM )
reduced adrenaline stimulated
GSK-3beta Ser9 phosphorylation but did not influence the effects of insulin
O'Driscoll et al., J Neurochem 2007
:
The effects of bFGF on
GSK3beta were
dependent on
protein kinase A (PKA) activation, as inhibition of this pathway blocked inactivation
Torii et al., Cell Signal 2008
:
Based on another finding indicating that Wnt5a upregulated PKA mediated phosphorylation of glycogen synthase kinase-3beta ( GSK-3beta ) at serine 9 that caused inactivation of GSK-3beta and subsequently resulted in activation of the beta-catenin pathway, we have speculated that the Wnt5a anti-apoptotic activity may be partially mediated by
PKA mediated phosphorylation of
GSK-3beta and subsequent activation of the beta-catenin pathway
Hayashi et al., Thromb Haemost 2009
:
These results suggested that cAMP elevating agents have two effects on PI3K signalling : inhibition of Akt phosphorylation independent of PKA ; and stimulation of
GSK-3beta phosphorylation
dependent on
PKA